Overview Dividends

(VEEV) Veeva Systems - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9224751084

Cloud, CRM, Vault, Clinical, Data

Health Care Technology
Market Cap in USD: 36,470m

IPO / Inception: 2013-10-16
Return 12m vs S&P 500: -10.5%

EPS (Earnings per Share)

EPS CAGR: 24.39%
EPS Trend: 90.2%

Last SUE: 1.54
Qual. Beats: 13

Revenue

Rev. CAGR: 14.67%
Rev. Trend: 98.7%

Last SUE: 1.91
Qual. Beats: 8

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	31.2%
Value at Risk 5%th	44.5%
Relative Tail Risk	-13.37%

Reward TTM
Sharpe Ratio	0.14
Alpha	-12.29
CAGR/Max DD	0.40

Character TTM
Hurst Exponent	0.566
Beta	0.603
Beta Downside	0.633

Drawdowns 3y
Max DD	29.64%
Mean DD	8.78%
Median DD	6.99%

Description: VEEV Veeva Systems December 04, 2025

Veeva Systems Inc. (NYSE: VEEV) delivers a suite of cloud-based software solutions tailored to the life-sciences sector, spanning commercial, data, development, and quality clouds. Its flagship offerings include the Veeva Commercial Cloud (Vault CRM, Veeva Medical, PromoMats, Crossix), the Veeva Data Cloud (OpenData, Link, Compass, CRM Pulse), and the Veeva Development Cloud (Clinical Platform, Data Management, Safety, RIM), complemented by consulting and managed-services support.

Key performance indicators from FY 2024 show revenue of roughly $2.2 billion, a year-over-year growth rate of ≈ 20 %, and a gross margin consistently above 85 %, reflecting the high-margin nature of SaaS licensing. The company’s subscription annual recurring revenue (ARR) grew at a compound annual growth rate (CAGR) of ≈ 30 % over the past three years, and its net-retention rate remained north of 120 %, indicating strong upsell and cross-sell dynamics.

Economic and sector drivers underpinning Veeva’s outlook include: (1) sustained global pharmaceutical R&D spending, projected to exceed $1 trillion by 2026, fueling demand for clinical-trial and regulatory software; (2) accelerating digital transformation mandates from regulators (e.g., FDA’s 2023 data-integrity guidance) that push life-science firms toward compliant cloud platforms; and (3) the broader shift toward subscription-based SaaS models, which improves revenue visibility and reduces capital intensity for customers.

For a deeper dive into VEEV’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven overview.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (860.3m TTM) > 0 and > 6% of Revenue (6% = 184.8m TTM)

FCFTA 0.17 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 200.2% (prev 172.8%; Δ 27.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 1.38b > Net Income 860.3m (YES >=105%, WARN >=100%)

Net Debt (-1.57b) to EBITDA (908.7m) ratio: -1.73 <= 3.0 (WARN <= 3.5)

Current Ratio 7.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (168.0m) change vs 12m ago 1.80% (target <= -2.0% for YES)

Gross Margin 75.67% (prev 73.93%; Δ 1.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 42.34% (prev 41.17%; Δ 1.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.26 (EBITDA TTM 908.7m / Interest Expense TTM -263.2m) >= 6 (WARN >= 3)

Altman Z'' 11.55

(A) 0.76 = (Total Current Assets 7.11b - Total Current Liabilities 944.9m) / Total Assets 8.10b

(B) 0.51 = Retained Earnings (Balance) 4.12b / Total Assets 8.10b

(D) 3.91 = Book Value of Equity 4.13b / Total Liabilities 1.06b

Total Rating: 11.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.55

1. Piotroski 4.50pt

2. FCF Yield 4.53%

3. FCF Margin 43.98%

4. Debt/Equity 0.01

5. Debt/Ebitda -1.73

6. ROIC - WACC (= 1.80)%

7. RoE 13.38%

8. Rev. Trend 98.71%

9. EPS Trend 90.19%

What is the price of VEEV shares?

As of December 29, 2025, the stock is trading at USD 224.65 with a total of 757,363 shares traded.
Over the past week, the price has changed by +0.58%, over one month by -6.51%, over three months by -23.33% and over the past year by +6.23%.

Is VEEV a buy, sell or hold?

Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.

Strong Buy: 12
Buy: 7
Hold: 11
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the VEEV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	312.2	39%
Analysts Target Price	312.2	39%
ValueRay Target Price	224.7	0%

VEEV Fundamental Data Overview December 22, 2025

Market Cap USD = 36.47b (36.47b USD * 1.0 USD.USD)
P/E Trailing = 43.332
P/E Forward = 25.7069
P/S = 11.8399
P/B = 5.1799
P/EG = 1.0191
Beta = 1.055
Revenue TTM = 3.08b USD
EBIT TTM = 858.9m USD
EBITDA TTM = 908.7m USD
Long Term Debt = 89.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 89.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.57b USD (from netDebt column, last quarter)
Enterprise Value = 29.92b USD (36.47b + Debt 89.8m - CCE 6.64b)
Interest Coverage Ratio = -3.26 (Ebit TTM 858.9m / Interest Expense TTM -263.2m)
FCF Yield = 4.53% (FCF TTM 1.35b / Enterprise Value 29.92b)
FCF Margin = 43.98% (FCF TTM 1.35b / Revenue TTM 3.08b)
Net Margin = 27.93% (Net Income TTM 860.3m / Revenue TTM 3.08b)
Gross Margin = 75.67% ((Revenue TTM 3.08b - Cost of Revenue TTM 749.5m) / Revenue TTM)
Gross Margin QoQ = 75.41% (prev 75.26%)
Tobins Q-Ratio = 3.70 (Enterprise Value 29.92b / Total Assets 8.10b)
Interest Expense / Debt = 33.69% (Interest Expense 30.2m / Debt 89.8m)
Taxrate = 24.48% (76.6m / 312.8m)
NOPAT = 648.6m (EBIT 858.9m * (1 - 24.48%))
Current Ratio = 7.53 (Total Current Assets 7.11b / Total Current Liabilities 944.9m)
Debt / Equity = 0.01 (Debt 89.8m / totalStockholderEquity, last quarter 7.04b)
Debt / EBITDA = -1.73 (Net Debt -1.57b / EBITDA 908.7m)
Debt / FCF = -1.16 (Net Debt -1.57b / FCF TTM 1.35b)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.63% (Net Income 860.3m / Total Assets 8.10b)
RoE = 13.38% (Net Income TTM 860.3m / Total Stockholder Equity 6.43b)
RoCE = 13.17% (EBIT 858.9m / Capital Employed (Equity 6.43b + L.T.Debt 89.8m))
RoIC = 10.09% (NOPAT 648.6m / Invested Capital 6.43b)
WACC = 8.28% (E(36.47b)/V(36.56b) * Re(8.24%) + D(89.8m)/V(36.56b) * Rd(33.69%) * (1-Tc(0.24)))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
[DCF Debug] Terminal Value 79.58% ; FCFE base≈1.23b ; Y1≈1.42b ; Y5≈2.01b
Fair Price DCF = 203.3 (DCF Value 33.42b / Shares Outstanding 164.4m; 5y FCF grow 17.99% → 3.0% )
EPS Correlation: 90.19 | EPS CAGR: 24.39% | SUE: 1.54 | # QB: 13
Revenue Correlation: 98.71 | Revenue CAGR: 14.67% | SUE: 1.91 | # QB: 8
EPS next Quarter (2026-04-30): EPS=2.06 | Chg30d=+0.041 | Revisions Net=+6 | Analysts=20
EPS next Year (2027-01-31): EPS=8.58 | Chg30d=+0.122 | Revisions Net=+22 | Growth EPS=+8.1% | Growth Revenue=+12.1%

Additional Sources for VEEV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle